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Risk of further decline in renal function after the use of oral
sodium phosphate or polyethylene glycol in patients with a
preexisting glomerular filtration rate below 60 ml/min
Abstract
OBJECTIVES: The aim of this study was to estimate the risk of further creatinine increase in patients
with preexisting renal disease after the use of oral sodium phosphate (OSP) versus polyethylene glycol
(PEG), and to study usage patterns of OSP in relation to renal function. METHODS: A cohort study was
done using clinical records and electronic patient information from the Henry Ford Health System
(HFHS) in patients who had used either OSP or PEG for colonoscopy between February 1999 and April
2006. Among patients with an estimated GFR <60 ml/min before colonoscopy, we identified cases with
an unexplained creatinine increase of >/=0.5 mg/dl within 14 days after colonoscopy. RESULTS: We
identified 7,971 OSP and 1,511 PEG users. Relative use of OSP versus PEG decreased from 88.0%
before 2004 to 48.4% in 2006. 70.2% of OSP users had no recorded creatinine determination within 60
days before colonoscopy, and this proportion did not decrease over time. The study population included
317 patients with a baseline GFR <60 ml/min, and we identified one case with an unexplained creatinine
increase >/=0.5 mg/dl among 191 PEG users (0.5%) versus eight cases among 126 OSP users (6.3%).
Unadjusted and adjusted relative risk estimates on comparing OSP with PEG were 12.1 (95% CI,
1.5-95.8) and 12.6 (95% CI, 1.5-106.5), respectively. CONCLUSIONS: In patients with preexisting
renal disease, OSP use was associated with an increased risk of aggravated renal dysfunction versus
PEG. Creatinine measurement with GFR estimation should be done before OSP administration in order
to avoid its use in patients with renal disease.
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ABSTRACT 
 
Objectives: To estimate the risk of further creatinine increase in patients with 
preexisting renal disease after use of oral sodium phosphate (OSP) vs. polyethylenglycol 
(PEG), and to study usage patterns of OSP in relation to renal function. 
Methods: Cohort study using clinical records and electronic patient information from the 
Henry Ford Health System (HFHS) in patients who had used either OSP or PEG for 
colonoscopy between February 1999 and April 2006. Among patients with an estimated 
(MDRD) GFR <60 ml/min before colonoscopy, we identified cases with an unexplained 
creatinine increase of ≥0.5 mg/dl within 14 days after colonoscopy. 
Results: We identified 7,971 OSP and 1,511 PEG users. Relative use of OSP vs. PEG 
decreased from 88.0% before 2004 to 48.4% in 2006. 70.2% of OSP users had no 
recorded creatinine determination within 60 days before colonoscopy, and this 
proportion did not decrease over time. The study population included 317 patients with a 
baseline GFR <60 ml/min, and we identified one case with an unexplained creatinine 
increase ≥0.5 mg/dl among 191 PEG users (0.5%) vs. eight cases among 126 OSP 
users (6.3%). Unadjusted and adjusted relative risk estimates comparing OSP with PEG 
were 12.1 (95% CI, 1.5-95.8) and 12.6 (95% CI, 1.5-106.5), respectively. 
Conclusions: In patients with preexisting renal disease OSP use was associated with 
an increased risk of aggravated renal dysfunction vs. PEG. Creatinine measurement 
with GFR estimation should be done before OSP administration in order to avoid its use 
in patients with renal disease. 
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INTRODUCTION 
Although oral sodium phosphate-containing bowel preparations (OSP) were 
found to be effective and safe in clinical trials (1, 2), a number of well-documented case 
reports suggested a causal relationship between OSP use and renal dysfunction at least 
in individual cases (3-5). Current mechanistic hypotheses focus on OSP-induced fluid 
and electrolyte dysbalances causing an increased phosphate-calcium product and 
possibly also decreased renal perfusion, particularly when hydration is insufficient (6-16). 
In line with these hypotheses there are two distinct safety concerns, i.e. irreversible 
acute renal failure (acute phosphate nephropathy / nephrocalcinosis), and usually 
reversible renal dysfunction of variable degree. Risk factors for renal dysfunction after 
OSP use have been proposed, and those are listed in the product information; e.g. the 
use of Fleet® Phosphosoda® EZ-PrepTM is not recommended in patients with clinically 
significant impairment of renal function, heart failure or ascites; and special caution is 
recommended in the elderly, in patients taking medications known to affect renal 
perfusion or function, with dehydration, or those taking drugs that affect fluid and 
electrolyte balance. In addition, the need for adequate hydration is emphasized and 
there is a warning not to exceed the recommended dose. 
Whereas clinical studies tend to include a healthier population than that later 
exposed in clinical practice and do not consider how “real-life” drug usage may affect the 
risk of adverse effects, case reports allow no quantification of adverse drug effects. 
Several observational studies have therefore studied the risk of renal dysfunction 
associated with OSP use in clinical practice (17-21). Compared to polyethylenglycol 
(PEG) some studies found a similar risk (18, 21), whereas one study reported an 
approximately doubling of the risk (19). Data sources and methods differed between 
these observational studies, and a conflicting debate about the safety of OSP continues 
(22-24). 
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In our own previous study, we found no significant difference in the risk of renal 
dysfunction after colonoscopy comparing OSP with PEG (21). In this study patients with 
preexisting renal disease including all patients with an estimated glomerular filtration rate 
(GFR) below 60 ml/min were excluded, because we primarily aimed to study the risk of 
incident renal disease in those in whom OSP use was compatible with current 
recommendations. However, during identification of the study population we found that a 
substantial proportion of OSP users had preexisting renal dysfunction. Therefore, usage 
patterns of OSP in clinical practice, and the question whether preexisting renal function 
may modify the risk of (additional) renal dysfunction associated with OSP merit further 
investigation. 
With the current study we now aimed to evaluate the risk of further creatinine 
increase in patients with preexisting renal dysfunction after use of OSP or PEG for 
colonoscopy. Furthermore we wanted to describe patient characteristics and usage 
patterns of OSP and PEG in relation to renal function. 
 
METHODS 
Data Source 
Information for this study was derived from the procedure database of the 
Gastroenterology Department at Henry Ford Hospital (HFH), Detroit, MI, and the 
administrative databases within the Henry Ford Health System (HFHS). The 
Gastroenterology database contains detailed information on colonoscopies including 
date, bowel cleansing preparation, and adequacy of preparation, as well as the medical 
record number as a unique patient identifier that allows linkage to the HFHS 
administrative databases and electronic medical records. The HFHS database contains 
information on medical care encounters, diagnoses, procedures, outpatient drug 
prescriptions, laboratory results and patient demographics. Additionally, for patients 
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enrolled in Health Alliance Plan (HAP), an HFHS owned and operated health 
maintenance organization, external claims for care are also available. Drug prescriptions 
are coded using the National Drug Code (NDC) provided by the United States Food and 
Drug Administration (FDA). All diagnoses are coded using the International Classification 
of Diseases, Clinical Modification (ICD-9 CM) coding system; procedures are coded 
using the Current Procedural Terminology-(CPT-4) coding system. All events are noted 
with the date on which the initial service was delivered. We also had access to original 
medical records and laboratory results of all patients enrolled in HAP. 
 The HFHS Human Rights Committee approved the study with a waiver of 
authorization. 
  
Study Population 
 The study was conducted among the base population of all patients who had a 
colonoscopy at the HFHS Detroit center gastroenterology clinic between 1 February 
1999 and 30 April 2006, who received oral bowel cleansing preparations containing 
either OSP (Phospho-soda®, C.B. Fleet Company, Inc., Lynchburg, VA, USA) or PEG 
(COLYTE®, Schwarz Pharma, Inc., Milwaukee, WI, USA), and were enrolled in the HAP 
for at least 6 months prior to and at least 4 weeks post colonoscopy. From those patients 
we obtained all creatinine values determined within 60 days prior to and 14 days post 
colonoscopy, and calculated GFR estimates according to the MDRD study formula (25). 
From this base population we subsequently excluded patients according to the following 
criteria: diagnoses or claims relating to dialysis within 6 months prior colonoscopy (in 
dialysis patients creatinine values do not reflect renal function), no creatinine 
determination within 60 days prior to colonoscopy, last GFR before colonoscopy ≥60 
ml/min, and/or no creatinine determination 14 days post colonoscopy. This selection 
process assured that our final study population included only patients with preexisting 
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renal dysfunction and sufficient information for identification and differential diagnostic 
evaluation of further renal impairment in relation to PEG or OSP exposure. 
We also extracted additional electronic information on demographics, preexisting 
concomitant drug use and comorbidities for all patients in the study population. Drug 
prescriptions within 3 months prior to colonoscopy were identified as a proxy for current 
drug use. For the identification of comorbidities we searched for related diagnostic codes 
or procedures within 12 months prior to colonoscopy. In addition to specific conditions of 
interest, the diagnostic coding was used to calculate the Charlson comorbidity index. 
Originally developed to assess survival probability based on inpatient medical record 
review, this methodology is also useful with administrative databases as a means of 
measuring underlying burden of illness (26, 27). 
 
Definition, identification and validation of cases 
 From the study population we identified all patients where plasma creatinine 
increased by at least 0.5 mg/dl within 14 days after colonoscopy vs. the last value before 
colonoscopy. Restriction to a short observation period after colonoscopy was based on 
the assumption that renal dysfunction in relation to bowel preparation products would 
manifest soon thereafter, and that particularly in patients with preexisting renal 
dysfunction who often also have other comorbidities a longer time period would increase 
the risk of misclassifying creatinine increase due to other reasons or “natural” 
fluctuations as related to bowel preparation exposure. Two physicians and one 
pharmacist with expertise in causality assessment of suspected adverse drug reactions 
then reviewed the original clinical records (SR) or abstracted case summaries (JKJ and 
SPM) of these patients, while being blinded with regard to the bowel preparation agent 
used (this information is not part of the clinical records but kept in the Gastroenterology 
database, which was later incorporated into the main dataset for the final analysis). 
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Patients with an identifiable likely cause of further renal impairment other than bowel 
preparation were subsequently excluded. The remaining patients were considered as 
“idiopathic” cases of further renal impairment and therefore to have at least a possible 
causal relationship to colonoscopy with bowel preparation. 
 
Data Analysis 
We calculated the incidence of further renal impairment during the 14-day period 
after colonoscopy, and estimated the unadjusted relative risk (RR) in patients receiving 
OSP vs. PEG as the period incidence ratio for these two groups. We used multivariate 
logistic regression in order to calculate odds ratios as an estimate of relative risks, and to 
control for the possible effects of patient demographics, drug use and comorbidities at 
the time of colonoscopy. In addition, we used propensity score methodology as an 
alternative way to control for confounding, i.e. we generated a logistic regression model 
that calculated a patient’s propensity to receive OSP or PEG based on patient 
demographics, current drug use and medical history. Subsequently we used this 
propensity score as a continuous covariate in a logistic regression model that measured 
the association between bowel preparation and further renal impairment (28). Data was 
analyzed using STATA 8.2 for MacOS X (STATA Corp LP, College Station, TX). 
 
RESULTS 
Identification of the base population, study population and cases are summarized 
in Figure 1. We identified a base population of 9,482 patients with continuous health plan 
enrollment that underwent colonoscopy and used either OSP (n=7,971) or PEG 
(n=1,511) for bowel preparation. One hundred and fifty-seven patients had a recent 
history of dialysis. Among the remaining patients, 553 out of 1,390 PEG users (39.8%), 
and 5,572 out of 7,935 OSP users (70.2%) had no recorded creatinine measurement 
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within 60 days prior to colonoscopy; and also among 2,916 OSP users with an age ≥65 
years, 1,874 (64.3%) had no creatinine measurement within 60 days prior to 
colonoscopy. Of the remaining 837 PEG and 2,363 OSP users, 319 (38.1%) and 362 
(15.3%), respectively, had a GFR<60 ml/min. Finally, we excluded another 364 patients 
who had no creatinine determination within 14 days post colonoscopy, leading to a study 
population of 317 patients. 
Trends in bowel preparation use over time are presented in Figure 2. As shown, 
in the base population OSP was the preferred bowel preparation until about 2004; then, 
starting in 2004 and coincident with the publication of several reports of renal failure after 
OSP use (3, 5), relative use of OSP decreased from 88.0% before 2004 to 48.4% in 
2006. In the study population, which includes only patients with a GFR <60 ml/min, 
relative use of OSP was lower, i.e. 49.1% until 2004, and there was a further decrease in 
its relative use going down to 7.1% in 2006. 
The proportion of patients with an available creatinine value within 60 days 
before OSP use over time is presented in Figure 3. As shown, there was no trend 
towards increased determinations of creatinine before OSP exposure over time; a similar 
pattern was found when looking only at patients with an age ≥65 years (data not shown). 
Demographics and baseline characteristics of the study population are presented 
in Table 1. Compared to patients receiving OSP, a higher proportion of patients 
receiving PEG had a very low GFR below 30 ml/min, heart failure and other 
comorbidities according to the Charlson index. They were also more likely to have 
colonoscopy as an inpatient procedure. 
Within the study population, we identified 20 patients with an increase in 
creatinine of at least 0.5 mg/dl within 14 days after colonoscopy, based on the last 
creatinine value before and the first value after colonoscopy. Eleven patients had other 
identifiable causes for renal dysfunction and were therefore not included as cases; 
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detailed reasons for not classifying those patients as cases are listed in Table 2. Among 
the remaining 9 cases, creatinine eventually returned to baseline in 6 patients, but did 
not do so during follow-up of more than one year in 3 patients (one PEG and two OSP 
users). One patient with a baseline creatinine of 3.9 mg/dl had creatinine values above 5 
mg/dl during follow-up and finally progressed to end stage renal disease, and in the 
other two patients creatinine remained high at around 2.5 mg/dl (baseline 1.3 mg/dl) and 
3.5 mg/dl (baseline 2.7 mg/dl), respectively. In order to account for the possibility of a 
delayed increase in creatinine we also reviewed the records of another 25 patients with 
a creatinine increase ≥0.5 mg/dl within 14 days after colonoscopy but where the first 
creatinine value after colonoscopy was less than 0.5 mg/dl above the baseline value; 
however, an alternative plausible cause for these creatinine increases was identified in 
all those patients. 
Absolute and univariate relative risks of impaired renal function after colonoscopy 
in relation to baseline characteristics are presented in Table 3. As shown, use of OSP 
was significantly associated with further renal impairment when compared with PEG, but 
none of the other factors showed a significant association, neither in the univariate nor in 
the multivariate analyses. Adjusted relative risk estimates are presented in Table 4. 
Regardless of whether conventional logistic regression or propensity score methodology 
was used to control for confounding, adjusted relative risk estimates were similar to the 
unadjusted univariate relative risk and indicated an elevated risk of renal impairment 
after use of OSP vs. PEG. 
 
DISCUSSION 
Several observational studies have evaluated the risk of renal dysfunction 
associated with OSP use. Two studies, one of which did and one did not find an 
association of OSP with impaired renal function, included patients with creatinine 
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increases without a patient level medical record review for likely alternative causes (17, 
20); furthermore, one of those studies modeled GFR changes as a continuous outcome 
and used a control group without colonoscopy, which provides only limited control over 
indication bias (20). Among three other studies one reported an elevated risk with an 
odds ratio of 2.35 (95%CI 1.51 to 3.66), whereas the other two found no increased risk 
of renal dysfunction comparing OSP with PEG (18, 21). Data sources and methods 
including the exact outcome definition of renal dysfunction differed between these 
observational studies, which may provide an explanation for different results; but it is 
also worth mentioning that confidence intervals for risk estimates overlap between all 
three studies, and differences may therefore also be due to chance. Although all three 
studies had included only a limited number of patients and were therefore not sufficiently 
powered to detect differences for small absolute risks in the range of 1:1000 or less, they 
are reassuring in the sense that in spite of convincing case reports of renal failure after 
OSP use, these indeed appear to be rare events in patients without preexisting renal 
dysfunction. Nevertheless, it has been clearly shown that OSP can cause fluid and 
electrolyte dysbalances, and it is also physiologically plausible that these may 
subsequently lead to renal dysfunction, particularly in patients with preexisting risk 
factors (6-16). In that context it is of particular interest that the current study is the first 
that focused on a subpopulation with a preexisting low GFR, and that limited the follow-
up time to a short at risk period of only 14 days. On the one hand this led to a limited 
number of patients that could be included in the final study population and consequently 
also limited the statistical precision of relative risk estimates. On the other hand the 
likelihood of case misclassification due to other factors is decreased with a shorter 
follow-up time, particularly in patients with preexisting renal dysfunction with high 
intraindividual variability of creatinine values and most likely also a higher burden of 
comorbidities, which may themselves be associated with renal dysfunction. Also, 
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previous case reports as well as current mechanistic hypotheses suggest that renal 
dysfunction, should it be caused by OSP, occurs within days after colonoscopy. 
Therefore, this restrictive study design is an important and robust method to control for 
confounding. Furthermore, although we realize intrinsic limitations of observational non-
randomized studies, ethical reasons would preclude the exposure of patients with 
preexisting significant renal impairment to OSP in a randomized clinical trial, leaving an 
observational study as the only option to study OSP’s renal safety in this population. 
Our current study found a statistically significant association between OSP use 
and further substantial increase in creatinine values for patients with a preexisting GFR 
<60 ml/min in the unadjusted as well as in two separate adjusted analyses. Whereas the 
conventional logistic regression model may be unstable for our dataset where the 
number of covariates is high in relation to cases, the propensity score-based regression 
analysis can be expected to offer an advantage for the analysis of our data and should 
provide reasonable additional control of potentially confounding factors. Furthermore, 
none of the other covariates had a significant association with creatinine increase after 
OSP use, neither in the univariate analysis nor in the multivariate model. Therefore, in 
spite of limited patient numbers and consequently wide confidence intervals, our results 
do indicate an association between OSP use and further renal dysfunction in patients 
with a preexisting GFR <60 ml/min. This is an important finding that certainly supports 
current warnings not to use OSP in patients with preexisting renal disease. Interestingly, 
on the basis of renal phosphate handling kinetics Mishra et al. postulated that a GFR 
below 50 ml/min may be a threshold for the development of significant 
hyperphosphatemia after commonly used OSP doses (13). As far as other possible risk 
factors are concerned, we incorporated information on these factors in the propensity 
score analysis in order to achieve reliable control for possible related confounding 
regarding the risk estimate for OSP vs. PEG use. However, one must consider that the 
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reported univariate unadjusted risks for these factors are subject to confounding, and 
furthermore based on low numbers of cases with these factors. As mentioned above, the 
conventional multivariate regression model is not sufficiently reliable, and our study 
therefore does not allow a reliable estimation of independent risks associated with these 
factors. 
If preexisting renal disease modifies the effect of OSP use on renal function after 
colonoscopy, the drug usage patterns found in our study have important implications for 
the safe use of OSP in clinical practice. As seen in Figure 2, overall use of OSP 
decreased after 2004, and in patients with preexisting low GFR non-recommended use 
decreased from about 50% to less than 10%, which occurred in close temporal 
relationship with safety warnings and labeling changes for OSP. It is therefore likely that 
these had an impact on OSP use in clinical practice, causing both, an unspecific 
decrease of OSP use in patients without evidence for an increased risk of OSP-induced 
renal damage, as well as the desired avoidance of OSP in patients with preexisting renal 
dysfunction. However this trend was only documented for patients where recent 
creatinine values were available. Given that chronic renal impairment may remain 
clinically silent and undetected for a long time, it is worrisome that we did not observe a 
trend towards increased determinations of creatinine before OSP exposure, not even in 
OSP users with an age ≥65 years. Although this patient group has a high prevalence of 
renal impairment (29-31), screening for preexisting renal disease was apparently not 
done in the majority of patients. In the light of these findings, one may ask whether over-
the-counter availability of OSP may play a role, which might make it difficult to identify 
contraindications for OSP use including preexisting renal disease, and therefore 
contribute to the high proportion of patients without recent creatinine determinations. 
In summary, our results indicate that OSP use is associated with further and 
possibly irreversible creatinine increase in patients with preexisting renal impairment, 
 13 
whereas current evidence does not indicate an increased risk of renal dysfunction in 
OSP users without preexisting renal dysfunction when compared to PEG users. Drug 
usage pattern in clinical practice is a major issue in relation to the renal safety of OSP. In 
clinical practice, OSP use has recently decreased, but this change in drug use did not 
focus on at-risk populations. We must assume that a substantial number of patients with 
preexisting renal disease continues to be exposed to OSP because creatinine is not 
measured and renal dysfunction may therefore remain unrecognized. Therefore, it must 
be reemphasized that OSP should not be used in patients with moderate or severe renal 
impairment and that renal function should be monitored before and after colonoscopy in 
those at risk for renal dysfunction.  
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STUDY HIGHLIGHTS 
1) What Is Current Knowledge 
• Although case reports have suggested a causal relationship between acute 
renal failure and use of oral sodium phosphates (OSP) in several cases, 
neither clinical nor observational studies have consistently identified an 
association between use of OSP and renal dysfunction in patients without 
preexisting renal disease. 
• Non-recommended use of OSP by patients with impaired renal function is not 
uncommon in clinical practice. 
2) What Is New Here 
• In patients with a GFR <60 ml/min, OSP use was associated with further renal 
impairment after colonoscopy when compared to PEG. 
• We observed a recent increase in the use of PEG vs. OSP, particularly in 
patients with a low GFR. However, the proportion of OSP users with a 
creatinine determination in order to screen for renal dysfunction before 
colonoscopy remains stable and at a low level. 
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FIGURES AND TABLES 
 
 
Figure 1. Identification of study population and cases 
 
 
Figure 2. Comparative relative use of PEG and OSP in the base population and study 
population over time 
 
 
Figure 3. Proportion of OSP users in the base population with creatinine determinations 
within 60 days before colonoscopy over time 
 
 
(see separately uploaded graphic files for all figures) 
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Table 1. Baseline Characteristics of the Study Population 
 
PEG users 
(N=191) 
 
OSP users 
(N=126) 
 
 n (%) n (%) p-value1 
Female 99 (51.8) 73 (57.9) 0.29 
Age ≥65 133 (69.6) 98 (77.8) 0.11 
African American Race 100 (52.4) 62 (49.2) 0.58 
Year of Colonoscopy      
    1999 / 2000 44 (23.0) 32 (25.4) 0.63 
    2001 / 2002 27 (14.1) 35 (27.8) <0.01 
    2003 / 2004 47 (24.6) 47 (37.3) 0.02 
    2005 / 2006 73 (38.2) 12 (9.5) <0.01 
Inpatient colonoscopy 151 (79.0) 77 (61.1) <0.01 
GI bleeding 30 days prior colonoscopy 103 (53.9) 58 (46.0) 0.17 
Hospitalization 12 months prior 
colonoscopy 
98 (51.3) 51 (40.5) 0.06 
Baseline GFR <30 ml/min 45 (23.6) 16 (12.7) 0.02 
Baseline comorbidities2      
    Diabetes mellitus 73 (38.2) 41 (32.5) 0.30 
    Congestive heart failure 79 (41.4) 37 (29.4) 0.03 
    Charlson comorbidity index ≥3 103 (53.9) 53 (42.1) 0.04 
Current drug therapy3      
    ACE inhibitors or ARB 88 (46.1) 52 (41.3) 0.40 
    Diuretics 111 (58.1) 69 (54.8) 0.56 
    Beta blockers 66 (34.6) 44 (34.9) 0.95 
    Calcium channel blockers 21 (11.0) 20 (15.9) 0.21 
    Nonsteroidal anti-inflammatory drugs 16 (8.4) 12 (9.5) 0.72 
 
1Chi-square two-sample test of proportion 
2Diagnoses within 12 months prior colonoscopy 
3Prescriptions within three months prior colonoscopy  
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Table 2. Reasons for exclusion of 11 patients with creatinine increase after colonoscopy 
from study cases because other likely causes of renal dysfunction were identified during 
review blinded to bowel preparation. 
 
No. Likely cause for renal dysfunction 
1. Creatinine increase started before colonoscopy; associated with urinary tract infection, 
heart failure and pneumonia. 
 
2. Obstructive uropathy; recovery of renal function after passage of urinary catheter. 
 
3. Hospital admission in unstable condition with diabetic ketoacidosis and foot gangrene; 
discharge letter also mentions acute renal failure secondary to nephrotoxic 
immunosuppressive drugs. 
 
4. Discharge letter describes dehydration with acute tubular necrosis before colonoscopy. 
 
5. Admitted in unstable condition with diabetes and severe anemia requiring transfusion. 
Pronounced fluctuations of creatinine values before colonoscopy. 
 
6. Neurogenic bladder with urinary retention. 
 
7. Creatinine increase started before colonoscopy; associated with dehydration and acute 
heart failure. 
 
8. Pronounced fluctuations of creatinine values before colonoscopy; associated with 
decompensated heart failure with anemia followed by forced diuresis. 
 
9. Pronounced fluctuations of creatinine values before colonoscopy; associated with rectal 
bleeding with severe anemia requiring transfusion, decompensated heart failure treated 
with forced diuresis. 
 
10. Very high creatinine values above 6 mg/dl with pronounced fluctuations before 
colonoscopy. Medical records indicate recent dialysis treatment. 
 
11. After colonoscopy infection requiring antibiotic treatment with clindamycin and 
ciprofloxacin plus intravenous fluids for dehydration. 
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Table 3. Absolute and univariate relative risks of impaired renal function after 
colonoscopy in relation to selected factors. 
 
 
Patients with factor 
and with ≥0.5 mg/dl 
creatinine increase1 
 
Patients without factor 
and with ≥0.5 mg/dl 
creatinine increase1 
 
  
Factors n Risk2a n Risk2b RR3 (95% CI) 
OSP use (vs. PEG) 8 6.3% 1 0.5% 12.1 (1.5-95.8) 
Female 6 3.5% 3 2.1% 1.7 (0.4-6.6) 
Age ≥65 years 6 2.6% 3 3.5% 0.7 (0.2-2.9) 
African American race 6 3.7% 6 1.9% 1.9 (0.5-7.5) 
Inpatient colonoscopy 5 2.2% 4 4.5% 0.5 (0.1-1.8) 
Hospitalization 12 months prior to 
colonoscopy 
1 0.7% 8 4.8% 0.1 (<0.1-1.1) 
GI bleeding 30 days prior 4 2.5% 5 3.2% 0.8 (0.2-2.8) 
GFR <30 ml/min 2 3.3% 7 2.7% 1.2 (0.3-5.6) 
Comorbidities4       
    Diabetes mellitus 2 1.7% 7 3.4% 0.5 (0.1-2.4) 
    Congestive heart failure 1 0.9% 8 4.0% 0.2 (<0.1-1.7) 
    Charlson index ≥2 3 1.9% 6 3.7% 0.5 (0.1-2.0) 
Current drug therapy5       
    ACE inhibitors or ARB6 4 2.9% 5 2.8% 1.0 (0.3-3.7) 
    Diuretics 5 2.8% 4 2.9% 1.0 (0.3-3.5) 
    Beta blockers 3 2.7% 6 2.9% 0.9 (0.2-3.7) 
    Calcium channel blockers 2 4.9% 7 2.5% 1.9 (0.4-8.9) 
    Nonsteroidal anti-inflammatories 1 3.6% 8 2.8% 1.3 (0.2-9.9) 
 
1At least 0.5 mg/dl creatinine increase within 14 days after colonoscopy 
2Risk of ≥0.5 mg/dl creatinine increase in patients with (2a) or without factor (2b). 
3Unadjusted relative risk (=risk ratio) of ≥0.5 mg/dl creatinine increase after colonoscopy for 
presence vs. absence of factor 
4Diagnoses within 12 months prior colonoscopy 
5Prescriptions within three months prior colonoscopy 
6Angiotensin converting enzyme inhibitors or angiotensin renin blockers 
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Table 4. Absolute numbers and risk of impaired renal function after colonoscopy, and 
adjusted odds ratios estimating the risk for renal impairment associated with OSP vs. 
PEG exposure. 
 
 All 
patients 
Cases with 
creatinine 
increase 
≥0.5 mg/dl 
Adjusted odds ratio 
using conventional 
logistic regression1 
(95% CI) 
Adjusted odds ratio using 
propensity score based 
logistic regression2 
(95% CI) 
 n n (risk)     
PEG 191 1 (0.5%) 1.0  (ref) 1.0 (ref) 
OSP 126 8 (6.3%) 14.4 (1.6-131.2) 12.6 (1.5-106.5) 
 
 
1Adjusted odds ratios and 95% confidence intervals estimated from a logistic regression model 
with case of creatinine increase as the outcome variable and the following cofactors: OSP use, 
age ≥65 yrs, female gender, African American race, baseline GFR <30 ml/min, congestive heart 
failure, diabetes mellitus, Charlson comorbidity score ≥4, inpatient colonoscopy, current use of 
angiotensin converting enzyme inhibitors or angiotensin renin blockers, calcium channel blockers, 
diuretics. 
2Propensity score predicting the likelihood of PEG or OSP use conditional on all other cofactors 
listed above for the conventional logistic regression model; this score was then used as a 
covariate in a logistic regression model where case of creatinine increase was the outcome 
variable and OSP exposure a cofactor. 
BASE POPULATION
Patients undergoing colonoscopy with PEG or OSP 
between Feb 1999 and Apr 2006, and enrollment in 
Health Aliance Plan 6 months prior to 4 weeks post 
colonoscopy.
Exclusions
Patients with dialysis within 6 months 
prior colonoscopy.
 
Patients without creatinine determination 
within 60 days prior colonoscopy.
Patients with GFR >60 ml/min
(last value before colonoscopy).
Patients without creatinine determination
within 14 days post colonoscopy. 
STUDY POPULATION
Patients with GFR<60 ml/min, available medical 
records, and creatinine determination within 60 
days prior and 14 days post colonoscopy.
CASES
Patients with aggravated renal 
impairment after colonoscopy.
Case identification and validation
Creatinine increase of at least 0.5 mg/dl 
within 14 days post colonoscopy (first value 
after minus last value before colonoscopy).
No cause for renal impairment identifiable in 
medical records.
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